Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neurology

24-04-2024 | COVID-19 | Original Communication

Neuropsychiatric complications of coronavirus disease 2019: Mount Sinai Health System cohort study

Authors: Kapil Gururangan, Veronica J. Peschansky, Grace Van Hyfte, Parul Agarwal, Leah J. Blank, Brian Mathew, Jonathan Goldstein, Churl-Su Kwon, Louise McCarthy, Ariella Cohen, Andy Ho Wing Chan, Pojen Deng, Mandip Dhamoon, Eveline Gutzwiller, Qing Hao, Celestine He, Britany Klenofsky, Hernan Nicolas Lemus, Lara Marcuse, Allison Navis, Wilson D. Heredia Nunez, Mallory N. Luckey, Emily M. Schorr, Anuradha Singh, Gabriela B. Tantillo, Claire Ufongene, James J. Young, Priti Balchandani, Joanne R. Festa, Georges Naasan, Alexander W. Charney, Girish N. Nadkarni, Nathalie Jetté, for the Sinai NeuroCOVID-19 Study Group

Published in: Journal of Neurology

Login to get access

Abstract

Objective

To describe the frequency of neuropsychiatric complications among hospitalized patients with coronavirus disease 2019 (COVID-19) and their association with pre-existing comorbidities and clinical outcomes.

Methods

We retrospectively identified all patients hospitalized with COVID-19 within a large multicenter New York City health system between March 15, 2020 and May 17, 2021 and randomly selected a representative cohort for detailed chart review. Clinical data, including the occurrence of neuropsychiatric complications (categorized as either altered mental status [AMS] or other neuropsychiatric complications) and in-hospital mortality, were extracted using an electronic medical record database and individual chart review. Associations between neuropsychiatric complications, comorbidities, laboratory findings, and in-hospital mortality were assessed using multivariate logistic regression.

Results

Our study cohort consisted of 974 patients, the majority were admitted during the first wave of the pandemic. Patients were treated with anticoagulation (88.4%), glucocorticoids (24.8%), and remdesivir (10.5%); 18.6% experienced severe COVID-19 pneumonia (evidenced by ventilator requirement). Neuropsychiatric complications occurred in 58.8% of patients; 39.8% experienced AMS; and 19.0% experienced at least one other complication (seizures in 1.4%, ischemic stroke in 1.6%, hemorrhagic stroke in 1.0%) or symptom (headache in 11.4%, anxiety in 6.8%, ataxia in 6.3%). Higher odds of mortality, which occurred in 22.0%, were associated with AMS, ventilator support, increasing age, and higher serum inflammatory marker levels. Anticoagulant therapy was associated with lower odds of mortality and AMS.

Conclusion

Neuropsychiatric complications of COVID-19, especially AMS, were common, varied, and associated with in-hospital mortality in a diverse multicenter cohort at an epicenter of the COVID-19 pandemic.
Literature
1.
Tsai L-K, Hsieh S-T, Chang Y-C (2005) Neurological manifestations in severe acute respiratory syndrome. Acta Neurol Taiwan 14(3):113–119PubMed
2.
Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, Saeed BT, Wahbi A, Saedy A, AlDabbagh T et al (2015) Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection 43(4):495–501PubMedPubMedCentralCrossRef
3.
Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM (2018) Neurologic alterations due to respiratory virus infections. Front Cell Neurosci 12(386):1–15
4.
Robinson CP, Busl KM (2020) Neurologic manifestations of severe respiratory viral contagions. Crit Care Expl 2(4):e0107
5.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720PubMedCrossRef
6.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77(6):683–690PubMedCrossRef
7.
Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C, Alberici A, Baldelli E, Benini M, Bonacina S et al (2020) Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology 95(7):e910–e920PubMedCrossRef
8.
Rifino N, Censori B, Agazzi E, Alimonti D, Bonito V, Camera G, Conti MZ, Foresti C, Frigeni B, Gerevini S et al (2021) Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. J Neurol 268(7):2331–2338PubMedCrossRef
9.
Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, Jayaseelan DL, Kumar G, Raftopoulos RE, Zambreanu L et al (2020) The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 143(10):3104–3120PubMedPubMedCentralCrossRef
10.
Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan M, Easton A, Breen G, Zandi M et al (2020) Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7(10):875–882PubMedPubMedCentralCrossRef
11.
Ross Russell AL, Hardwick M, Jeyanantham A, White LM, Deb S, Burnside G, Joy HM, Smith CJ, Pollak TA, Nicholson TR et al (2021) Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. Brain Commun 3(3):fcab168PubMedPubMedCentralCrossRef
12.
Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, Harrison PJ (2022) Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 9(10):815–827PubMedPubMedCentralCrossRef
13.
Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M et al (2020) Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382(23):2268–2270PubMedCrossRef
14.
Kremer S, Lersy F, Anheim M, Merdji H, Schenck M, Oesterlé H, Bolognini F, Messie J, Khalil A, Gaudemer A et al (2020) Neurologic and neuroimaging findings in patients with COVID-19: a retrospective multicenter study. Neurology 95(13):e1868–e1882PubMedCrossRef
15.
Meppiel E, Peiffer-Smadja N, Maury A, Bekri I, Delorme C, Desestret V, Gorza L, Hautecloque-Raysz G, Landre S, Lannuzel A et al (2021) Neurologic manifestations associated with COVID-19: a multicentre registry. Clin Microbiol Infect 27(3):458–466PubMedCrossRef
16.
Delorme C, Houot M, Rosso C, Carvalho S, Nedelec T, Maatoug R, Pitron V, Gassama S, Sambin S, Bombois S et al (2021) The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre. Brain Commun 3(3):fcab135PubMedPubMedCentralCrossRef
17.
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, González E, Redondo-Peñas I, Perona-Moratalla AB, Del Valle-Pérez JA et al (2020) Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology 95(8):e1060–e1070PubMedPubMedCentralCrossRef
18.
Portela-Sánchez S, Sánchez-Soblechero A, Otalora PJM, López AR, Alonso GV, Palacios-Mendoza MA, Caramé CC, Pascasio LA, Serrano MM, Massot-Tarrús A et al (2021) Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic. Eur J Neurol 28(10):3339–3347PubMedPubMedCentralCrossRef
19.
García-Moncó JC, Muras AC, Iriarte ME, Armenteros PR, Fernández AC, Arranz-Martínez J, Kapetanovic S, Lorenzo-García A, González AB, Gomez-Beldarrain M (2021) Neurologic manifestations in a prospective unselected series of hospitalized patients with COVID-19. Neurol Clin Pract 11(2):e64–e72PubMedPubMedCentralCrossRef
20.
Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger KA et al (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382(20):e60PubMedCrossRef
21.
Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, Koralnik IJ (2020) Frequent neurologic manifestations and encephalopathy-associated morbidity in COVID-19 patients. Ann Clin Transl Neurol 7(11):2221–2230PubMedPubMedCentralCrossRef
22.
Dhamoon MS, Thaler A, Gururangan K, Kohli A, Sisniega D, Wheelwright D, Mensching C, Fifi JT, Fara MG, Jette N et al (2021) Acute cerebrovascular events with COVID-19 infection. Stroke 52(1):48–56PubMedCrossRef
23.
Frontera JA, Sabadia S, Lalchan R, Fang T, Flusty B, Millar-Vernetti P, Snyder T, Berger S, Yang D, Granger A et al (2021) A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City. Neurology 96(4):e575–e586PubMedPubMedCentralCrossRef
24.
Agarwal P, Ray S, Madan A, Tyson B (2021) Neurological manifestations in 404 COVID-19 patients in Washington State. J Neurol 268(3):770–772PubMedCrossRef
25.
Chuang DT, Aydemir S, Magda P, Thomas C, Zarnegar R (2021) Neurological manifestations as primary presentation of COVID-19 in hospitalized patients. Acta Neurol Scand 143(5):569–574PubMedPubMedCentralCrossRef
26.
Eskandar EN, Altschul DJ, de la Garza RR, Cezayirli P, Unda SR, Benton J, Dardick J, Toma A, Patel N, Malaviya A et al (2021) Neurologic syndromes predict higher in-hospital mortality in COVID-19. Neurology 96(11):e1527–e1538PubMedPubMedCentralCrossRef
27.
Tantillo GB, Jetté N, Gururangan K, Agarwal P, Marcuse L, Singh A, Goldstein J, Kwon CS, Dhamoon MS, Navis A et al (2022) Electroencephalography at the height of a pandemic: EEG findings in patients with COVID-19. Clin Neurophysiol 137:102–112PubMedPubMedCentralCrossRef
28.
Thakur KT, Chu VT, Hughes C, Kim CY, Fleck-Derderian S, Barrett CE, Matthews E, Balbi A, Bilski A, Chomba M et al (2022) Risk factors for new neurologic diagnoses in hospitalized patients with COVID-19: a case-control study in New York City. Neurol Clin Pract 12(4):e66–e74PubMedPubMedCentralCrossRef
29.
Nori S, Moran A, Franolich J, Patel J, Stern M (2022) COVID-19 and neurologic manifestations: an experience at major New York City hospitals. Cureus 14(4):e24049PubMedPubMedCentral
30.
Chou SHY, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, Mainali S, Bassetti C, Suarez JI, McNett M et al (2021) Global incidence of neurological manifestations among patients hospitalized with COVID-19—a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open 4(5):e2112131PubMedPubMedCentralCrossRef
31.
32.
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T (2020) Neurological associations of COVID-19. Lancet Neurol 19(9):767–783PubMedPubMedCentralCrossRef
33.
34.
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 77(8):1018–1027PubMedPubMedCentralCrossRef
35.
Favas TT, Dev P, Chaurasia RN, Chakravarty K, Mishra R, Joshi D, Mishra VN, Kumar A, Singh VK, Pandey M, Pathak A (2020) Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci 41(12):3437–3470PubMedPubMedCentralCrossRef
36.
37.
Vitalakumar D, Sharma A, Kumar A, Flora SJS (2021) Neurological manifestations in COVID-19 patients: a meta-analysis. ACS Chem Neurosci 12(15):2776–2797CrossRef
38.
Paranjpe I, Russak AJ, De Freitas JK, Lala A, Miotto R, Vaid A, Johnson KW, Danieletto M, Golden E, Meyer D et al (2020) Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City. BMJ Open 10(11):e040736PubMedCrossRef
39.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130–1139PubMedCrossRef
40.
Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27PubMedCrossRef
41.
42.
Bodro M, Compta Y, Sánchez-Valle R (2021) Presentations and mechanisms of CNS disorders related to COVID-19. Neurol Neuroimmunol Neuroinflamm 8(1):e923PubMedCrossRef
43.
44.
Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, Lu P, Weizman OE, Liu F, Dai Y et al (2021) Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 218(3):e20202135PubMedPubMedCentralCrossRef
45.
Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, Chance R, Macaulay IC, Chou HJ, Fletcher RB et al (2020) Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 6(31):eabc5801PubMedPubMedCentralCrossRef
46.
Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JL, Padera RFJ, Sabeti P (2020) Neuropathological features of COVID-19. N Engl J Med 383(10):989–992PubMedCrossRef
47.
Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M et al (2020) Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 19(11):919–929PubMedPubMedCentralCrossRef
48.
Thakur KT, Miller EH, Glendinning MD, Al-Dalahmah O, Banu MA, Boehme AK, Boubour AL, Bruce SS, Chong AM, Claassen J et al (2021) COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain 144(9):2696–2708PubMedPubMedCentralCrossRef
49.
Suh J, Mukerji SS, Collens SI, Padera RF Jr, Pinkus GS, Amato AA, Solomon IH (2021) Skeletal muscle and peripheral nerve histopathology in COVID-19. Neurology 97(8):e849–e858PubMedCrossRef
50.
Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G, Zeidman A, Dangayach NS, Olin J, Kohli-Seth R, Powell CA (2020) COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin Transl Med 10(2):e44PubMedPubMedCentralCrossRef
51.
52.
Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, Dodd SJ, Koretsky AP, Watts JA, Cheung V et al (2021) Microvascular injury in the brains of patients with COVID-19. N Engl J Med 384(5):481–483PubMedCrossRef
53.
Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R, Hernandez T, Stock A, Zhao Z, AlRasheed MR et al (2021) Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol 34(8):1456–1467PubMedPubMedCentralCrossRef
54.
Bernard-Valnet R, Perriot S, Canales M, Pizzarotti B, Caranzano L, Castro-Jiménez M, Epiney JB, Vijiala S, Salvioni-Chiabotti P, Anichini A et al (2021) Encephalopathies associated with severe COVID-19 present neurovascular unit alterations without evidence for strong neuroinflammation. Neurol Neuroimmunol Neuroinflamm 8(5):e1029PubMedPubMedCentralCrossRef
55.
56.
Pilotto A, Masciocchi S, Volonghi I, De Giuli V, Caprioli F, Mariotto S, Ferrari S, Bozzetti S, Imarisio A, Risi B et al (2021) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis 73(9):e3019–e3026PubMedCrossRef
57.
Bartley CM, Johns C, Ngo TT, Dandekar R, Loudermilk RL, Alvarenga BD, Hawes IA, Zamecnik CR, Zorn KC, Alexander JR et al (2021) Anti-SARS-CoV-2 and autoantibody profiles in the cerebrospinal fluid of 3 teenaged patients with COVID-19 and subacute neuropsychiatric symptoms. JAMA Neurol 78(12):1503–1509PubMedCrossRef
58.
Alexopoulos H, Magira E, Bitzogli K, Kafasi N, Vlachoyiannopoulos P, Tzioufas A, Kotanidou A, Dalakas MC (2020) Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm 7(6):e893PubMedPubMedCentralCrossRef
59.
Espíndola OM, Gomes YCP, Brandão CO, Torres RC, Siqueira M, Soares CN, Lima MASD, Leite ACCB, Venturotti CO, Carvalho AJC et al (2021) Inflammatory cytokine patterns associated with neurological diseases in Coronavirus disease 2019. Ann Neurol 89(5):1041–1045PubMedPubMedCentralCrossRef
Metadata
Title
Neuropsychiatric complications of coronavirus disease 2019: Mount Sinai Health System cohort study
Authors
Kapil Gururangan
Veronica J. Peschansky
Grace Van Hyfte
Parul Agarwal
Leah J. Blank
Brian Mathew
Jonathan Goldstein
Churl-Su Kwon
Louise McCarthy
Ariella Cohen
Andy Ho Wing Chan
Pojen Deng
Mandip Dhamoon
Eveline Gutzwiller
Qing Hao
Celestine He
Britany Klenofsky
Hernan Nicolas Lemus
Lara Marcuse
Allison Navis
Wilson D. Heredia Nunez
Mallory N. Luckey
Emily M. Schorr
Anuradha Singh
Gabriela B. Tantillo
Claire Ufongene
James J. Young
Priti Balchandani
Joanne R. Festa
Georges Naasan
Alexander W. Charney
Girish N. Nadkarni
Nathalie Jetté
for the Sinai NeuroCOVID-19 Study Group
Publication date
24-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-024-12370-9